Eagle gets CRL for Ryanodex

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) said FDA issued a complete response letter for Ryanodex dantrolene (EP-4104) to treat exertional heat stroke. FDA has requested an additional clinical trial in the indication, and the company said it is considering its options...